PSMA diagnostics as well as PSMA-based RLT have already had tremendous influence on prostate cancer management and are going to furtherly shape diagnostic and treatment options for an increasing amount of PCa patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.